Related Experiment Video
Updated: May 7, 2026

Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin
Hans Zempel1, Julia Luedtke, Yatender Kumar
1DZNE, German Center for Neurodegenerative Diseases, Bonn, Germany.
Abstract:
Mislocalization and aggregation of Aβ and Tau combined with loss of synapses and microtubules (MTs) are hallmarks of Alzheimer disease. We exposed mature primary neurons to Aβ oligomers and analysed changes in the Tau/MT system. MT breakdown occurs in dendrites invaded by Tau (Tau missorting) and is mediated by spastin, an MT-severing enzyme. Spastin is recruited by MT polyglutamylation, induced by Tau missorting triggered translocalization of TTLL6 (Tubulin-Tyrosine-Ligase-Like-6) into dendrites. Consequences are spine loss and mitochondria and neurofilament mislocalization. Missorted Tau is not axonally derived, as shown by axonal retention of photoconvertible Dendra2-Tau, but newly synthesized. Recovery from Aβ insult occurs after Aβ oligomers lose their toxicity and requires the kinase MARK (Microtubule-Affinity-Regulating-Kinase). In neurons derived from Tau-knockout mice, MTs and synapses are resistant to Aβ toxicity because TTLL6 mislocalization and MT polyglutamylation are prevented; hence no spastin recruitment and no MT breakdown occur, enabling faster recovery. Reintroduction of Tau re-establishes Aβ-induced toxicity in TauKO neurons, which requires phosphorylation of Tau's KXGS motifs. Transgenic mice overexpressing Tau show TTLL6 translocalization into dendrites and decreased MT stability. The results provide a rationale for MT stabilization as a therapeutic approach.
Insights
Alzheimer disease involves Tau protein missorting into dendrites, causing microtubule (MT) breakdown and neuronal damage. Stabilizing MTs may offer a therapeutic strategy against this neurodegenerative condition.
Area of Science:
- Neuroscience
- Cell Biology
- Molecular Biology
Background:
- Alzheimer disease (AD) is characterized by amyloid-beta (Aβ) and Tau pathology, synaptic loss, and microtubule (MT) instability.
- Understanding the interplay between Aβ, Tau, and MT dynamics is crucial for developing effective AD therapies.
Purpose of the Study:
- To investigate the mechanisms underlying Aβ-induced Tau missorting and subsequent MT breakdown in neurons.
- To identify key molecular players involved in Tau/MT system alterations in AD pathogenesis.
- To explore the therapeutic potential of MT stabilization in AD.
Main Methods:
- Primary neuron cultures exposed to Aβ oligomers.
- Analysis of Tau/MT system dynamics, including Tau localization, MT stability, and synaptic integrity.
- Utilized Tau-knockout (TauKO) mouse models and transgenic mice overexpressing Tau.
- Investigated the roles of spastin, Tubulin-Tyrosine-Ligase-Like-6 (TTLL6), and Microtubule-Affinity-Regulating-Kinase (MARK).
Main Results:
- Aβ oligomers induce Tau missorting into dendrites, leading to MT breakdown mediated by spastin recruitment via MT polyglutamylation.
- TTLL6 translocalization into dendrites triggers MT polyglutamylation and spastin-mediated MT severing.
- Newly synthesized Tau, not axonally derived, is responsible for dendritic MT pathology.
- TauKO neurons exhibit resistance to Aβ toxicity due to prevention of TTLL6 mislocalization and MT polyglutamylation.
- MARK kinase is required for recovery from Aβ insult.
- Tau reintroduction in TauKO neurons restores Aβ toxicity, dependent on Tau phosphorylation.
- Tau overexpression in transgenic mice leads to TTLL6 translocalization and decreased MT stability.
Conclusions:
- Tau missorting into dendrites is a key mechanism driving MT breakdown and synaptic loss in response to Aβ oligomers.
- TTLL6 and spastin are critical mediators of Aβ-induced MT pathology.
- MT stabilization emerges as a promising therapeutic strategy for Alzheimer disease.
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Microtubule Associated Proteins (MAPs)
Destabilization of Microtubules
Assembly of Complex Microtubule Structures

